

trans-Hinokiresinol Datasheet

5th Edition (Revised in January, 2017)

[Product Information]

Name: trans-Hinokiresinol

Catalog No.: CFN99834

Cas No.: 17676-24-3

Purity: > 95%

M.F: C₁₇H₁₆O₂

M.W: 252.3

Physical Description: Powder

Synonyms: 4-[(3S)-1-(4-hydroxyphenyl)penta-1,4-dien-3-yl]phenol;

Hinokiresinol; 4,4'-(1Z,3S)-penta-1,4-diene-1,3-diyldiphenol.

[Intended Use]

- 1. Reference standards;
- 2. Pharmacological research;
- 3. Synthetic precursor compounds;
- 4. Intermediates & Fine Chemicals;
- 5. Others.

[Source]

The barks of Cryptomeria japonica.

[Biological Activity or Inhibitors]

Hinokiresinol (trans-hinokiresinol) and nyasol (cis-hinokiresinol) possess appreciable

estrogen receptor binding activity, they can stimulate the proliferation of estrogen-

dependent T47D breast cancer cells, and their stimulatory effects could be blocked by an

estrogen antagonist, indicating that they are estrogen agonists.[1]

trans- and cis-Hinokiresinols have similar free radical scavenging and anti-inflammatory

activities, they also have anti-ischemic effects, only trans-hinokiresinol can significantly

decrease neuronal injury in cultured cortical neurons exposed to oxygen-glucose

deprivation followed by re-oxygenation.[2]

Hinokiresinol is a novel inhibitor of LTB4 binding to the human neutrophils. [3]

Hinokiresinol has antiallergic effect, it inhibits IgE-induced mouse passive cutaneous

anaphylaxis reaction.[4]

[Solvent]

Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.

[HPLC Method]^[5]

Mobile phase: Acetonitrile-0.03%Phosphoric acid H2O, gradient elution;

Flow rate: 0.5 ml/min;

Column temperature: 30 °C;

The wave length of determination: 210 nm.

[Storage]

2-8°C, Protected from air and light, refrigerate or freeze.

[References]

[1] Minami E, Taki M, Takaishi S, et al. Chem. Pharm. Bull., 2000, 48(3):389-92.

[2] Ju C, Hwang S, Cho G S, et al. Neuropharmacology, 2013, 67(4):465-75.

[3] Lee H J, Ryu J H. Planta Med., 1999, 65(4):391.

[4] Bae E, Park E H, Baek N, et al. Planta Med., 2006, 72(14):1328-30.

[5] Luo J, Shi S H, Zhang L Q, et al. Chinese Pharmaceutical Journal, 2012, 47(22): 1856-9.

[Contact]

Address:

S5-3 Building, No. 111, Dongfeng Rd.,

Wuhan Economic and Technological Development Zone,

Wuhan, Hubei 430056,

China

Email: info@chemfaces.com

Tel: +86-27-84237783 **Fax:** +86-27-84254680

Web: www.chemfaces.com

Tech Support: service@chemfaces.com